How a leading biopharmaceutical company upgraded its content creation process

Deviating from familiarity can make people feel uncomfortable. At the same time, humans are adaptable; have you ever protested a software update for an app on your phone? You likely grumbled a little bit, but before you even realized it, you were moving on with your life, if not appreciating the improvements.

In the life sciences, a bulk of the content work done during the drug development lifecycle happens in programs like Microsoft Word because, though not necessarily the most efficient platform for the process, it works well enough — and it’s familiar. Additionally, the industry has long resisted using any other solution.

Has reluctance or avoidance to try new things resulted in slowing down the speed of innovation? Not for Boehringer Ingelheim.

Boehringer Ingelheim seeks out a better authoring solution

As a leading research-driven biopharmaceutical company, Boehringer Ingelheim realized they needed a platform that was more attuned to the requirements of biopharmaceutical documentation to keep pace with medical innovation and the demands of regulatory requirements. Structured Component Authoring (SCA) was on the radar for a while, but they needed to ensure it could work within the requirements of the industry.

By design, SCA offers many benefits, namely the capacity for many authors, reviewers, and approvers to collaborate on a single document at the same time. But, in the context of research and medical information authoring, an SCA solution must also enhance compliance by enabling the ability to reuse approved, compliant blocks of content within and across clinical, regulatory, medical, safety, CMC, and other documents.

For Boehringer Ingelheim, they realized SCA had the potential to boost efficiency across the publishing process, and after selecting Docuvera for its life sciences-specificity, they haven’t looked back.

Docuvera: Flexibility designed for Life Sciences

SCA has been around for a while, but medical authors need a solution that can work with multiple writers and reviewers, strict regulations, and can endure countless rounds of revisions and updates. At the same time, they also require a simple-to-use program that requires minimal training and IT maintenance or troubleshooting to use. For Boehringer Ingelheim, Docuvera’s SCA solution enabled them to maintain documentation, comply with regulatory specifications, and submit structured information required by organizations such as the European Medicines Agency — and it was easy to use.

An intuitive implementation to get up and running quickly

One of the top benefits of Docuvera lies in its user experience. The interface feels familiar and intuitive, much like typical word-processing programs. Because of this, Boehringer Ingelheim experienced a swift and smooth rollout of Docuvera; when a platform isn’t overly technical, anybody can instinctively use it without undergoing training for months.

A solution specifically created for a complex process

At Docuvera, we deeply understand the life sciences industry and the content authoring, review, and approval process. From highly-tailored service plans for each client to a full suite of support engagements, ongoing training, and support, as well as a dedicated Customer Success Manager, we know that no two organizations are the same, so we make our customers a priority from first contact.

Check out how we helped leading biopharmaceutical research company Boehringer Ingelheim trade Microsoft Word for structured component authoring to improve their Life Sciences documentation process. View the full case study.